GlassScriptPhysician profile
Chung-Che Chang
NPI 1194773663
$25,063.62
in general payments reported to CMS, 2019-2025
10 companies · $3,119 in 2025
The $3,119 reported for 2025 was more than what 92% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,354 · 2020: $1,875 · 2021: $1,107 · 2022: $4,865 · 2023: $5,425 · 2024: $318 · 2025: $3,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,857 · Travel and Lodging: $1,721 · Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,856.67 |
| Travel and Lodging | $1,721.44 |
| Food and Beverage | $1,284.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,521.33 | 2019-2025 | Enhertu |
| Adaptive Biotechnologies Corporation | $3,113.68 | 2021-2023 | Clonoseq |
| Incyte Corporation | $1,607.31 | 2020-2025 | Jakafi, Jakafi, Monjuvi |
| Becton, Dickinson and Company | $1,016.67 | 2020-2023 | |
| Illumina, INC. | $281.90 | 2023-2025 | Oncology Testing |
| Pillar Biosciences, INC | $125.56 | 2024 | |
| Astellas Pharma US INC | $124.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.54 | 2019 | |
| Medline Industries LP | $84.40 | 2024-2025 | |
| Stemline Therapeutics INC. | $66.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chung-Che Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.